BD (Becton Dickinson and Company), one of the world’s largest medical technology firms, has appointed Francesca DeMartino as its new senior vice president of investor relations, effective today.
Reporting to Chris DelOrefice, executive vice president and chief financial officer for BD, DeMartino succeeds Kristen Stewart – who has been named senior vice president of enterprise strategy and insights for BD. Stewart, a top analyst before moving into investor relations, joined BD in August 2020, in what was then a new role for the Franklin Lakes, New Jersey-headquartered company.
DeMartino is now tasked with communicating progress of the firm’s BD2025 strategy to investors and the financial community, ‘including the company’s initiatives that drive shareholder value,’ according to a statement announcing her appointment.
‘Francesca is an accomplished leader with a long track record of success in investor relations, including extensive experience in the medical technology industry,’ says DelOrefice, in the company statement. ‘She will lead BD’s efforts to highlight key milestones as we deliver on our strategy to drive growth through innovation.’
BD highlights DeMartino’s more than 20 years of combined experience across IR, communications and corporate finance – noting that she most recently served as vice president of investor relations at Medtronic. ‘During her tenure, the function received IR Magazine Awards for best overall investor relations and best investor relations in healthcare,’ adds BD.
Prior to Medtronic, DeMartino – who began her career as a financial analyst at Deutsche Group – held positions ‘of increasing responsibility’ at Johnson & Johnson, OMRIX Biopharmaceuticals, Macrocure, GCI Group and The Ruth Group.
